All In Biotech

Drug Trial Radar · NCT02085408

Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)

Last checked: Nov 20, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 727 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

727

Actual

Start

Feb 4, 2011

Primary completion

Feb 22, 2021

Study completion Dec 21, 2022

Sponsor

Lead sponsor
ECOG-ACRIN Cancer Research GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Mar 12, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as clofarabine, daunorubicin hydrochloride, cytarabine, and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which chemotherapy regimen is more effective in treating acute myeloid leukemia.

Conditions

  • Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
  • Adult Acute Megakaryoblastic Leukemia (M7)
  • Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
  • Adult Acute Monoblastic Leukemia (M5a)
  • Adult Acute Monocytic Leukemia (M5b)
  • Adult Acute Myeloblastic Leukemia With Maturation (M2)
  • Adult Acute Myeloblastic Leukemia Without Maturation (M1)
  • Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
  • Adult Acute Myeloid Leukemia With Del(5q)
  • Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
  • Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
  • Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
  • Adult Acute Myelomonocytic Leukemia (M4)
  • Adult Erythroleukemia (M6a)
  • Adult Pure Erythroid Leukemia (M6b)
  • Secondary Acute Myeloid Leukemia
  • Untreated Adult Acute Myeloid Leukemia

Interventions

  • DaunorubicinDrug

    Given IV

  • CytarabineDrug

    Given IV

  • ClofarabineDrug

    Given IV

  • DecitabineDrug

    Given IV

  • ObservationOther

    Undergo clinical observation

  • Allogeneic hematopoietic stem cell transplantationProcedure

    Patients with an HLA-identical donor proceed to allogeneic stem cell transplantation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Assessed every 3 months for 4 years and then every 6 months for 1 year

Locations

269 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • Arizona Cancer Center at University Medical Center North

    Tucson, Arizona

  • University of Arizona Health Sciences Center

    Tucson, Arizona

  • The Medical Center of Aurora

    Aurora, Colorado

  • Boulder Community Hospital

    Boulder, Colorado

  • Penrose-Saint Francis Healthcare

    Colorado Springs, Colorado

  • Saint Anthony Central Hospital

    Denver, Colorado

  • Porter Adventist Hospital

    Denver, Colorado

  • Exempla Saint Joseph Hospital

    Denver, Colorado

  • Presbyterian - Saint Lukes Medical Center - Health One

    Denver, Colorado

  • Rose Medical Center

    Denver, Colorado

  • Colorado Cancer Research Program CCOP

    Denver, Colorado

  • Swedish Medical Center

    Englewood, Colorado

  • North Colorado Medical Center

    Greeley, Colorado

  • Littleton Adventist Hospital

    Littleton, Colorado

  • Sky Ridge Medical Center

    Lone Tree, Colorado

  • Longmont United Hospital

    Longmont, Colorado

  • McKee Medical Center

    Loveland, Colorado

  • Parker Adventist Hospital

    Parker, Colorado

  • Saint Mary Corwin Medical Center

    Pueblo, Colorado

  • North Suburban Medical Center

    Thornton, Colorado

  • Exempla Lutheran Medical Center

    Wheat Ridge, Colorado

  • Saint Francis Hospital and Medical Center

    Hartford, Connecticut

  • The Hospital of Central Connecticut

    New Britain, Connecticut

  • Beebe Medical Center

    Lewes, Delaware

  • Christiana Care Health System-Christiana Hospital

    Newark, Delaware

  • University of Florida

    Gainesville, Florida

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • Florida Hospital

    Orlando, Florida

  • Piedmont Hospital

    Atlanta, Georgia

  • Atlanta Regional CCOP

    Atlanta, Georgia

  • Northside Hospital

    Atlanta, Georgia

  • Saint Joseph's Hospital of Atlanta

    Atlanta, Georgia

  • Georgia Regents University

    Augusta, Georgia

  • Well Star Cobb Hospital

    Austell, Georgia

  • John B Amos Cancer Center

    Columbus, Georgia

  • Dekalb Medical Center

    Decatur, Georgia

  • Piedmont Fayette Hospital

    Fayetteville, Georgia

  • Gwinnett Medical Center

    Lawrenceville, Georgia

Showing 40 of 269 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.